Evelyne Lima-Fernandes

Evelyne Lima-Fernandes

Auto-generated profile, based on publicly available information

Evelyne Lima-Fernandes

INSERM, U1016, Institut Cochin, Paris, France

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Nature Medicine
Verified
Journal Article
Closed access
AKAntonija Kreso
Antonija Kreso
PGPeter van Galen
Peter van Galen
NPNicholas M Pedley
Nicholas M Pedley
ELEvelyne Lima-Fernandes
Evelyne Lima-Fernandes
CFCatherine Frelin
Catherine Frelin
COCatherine A O'Brien
Catherine A O'Brien

21 August 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
QWQin Wu
Qin Wu
WBWail Ba-Alawi
Wail Ba-Alawi
GDGenevieve Deblois
Genevieve Deblois
JCJennifer Cruickshank
Jennifer Cruickshank
SDShili Duan
Shili Duan
CACheryl H. Arrowsmith
Cheryl H. Arrowsmith
Triple negative breast cancer (TNBC) is a deadly form of breast cancer due to the development of resistance to chemotherapy affecting over 30% of patients. New therapeutics and companion biomarkers are urgently needed. Recognizing the elevated expression of glucose transporter 1 (GLUT1, encoded by SLC2A1) and associated metabolic dependencies in TNBC, we investigated the vulnerability of TNBC cell lines and patient-derived samples to GLUT1 inhibition. We report that genetic or pharmacological inhibition of GLUT1 with BAY-876 impairs the growth of a subset of TNBC cells displaying high glycolytic and lower oxidative phosphorylation (OXPHOS) rates. Pathway enrichment analysis of gene expression data suggests that the functionality of the E2F pathway may reflect to some extent OXPHOS activity. Furthermore, the protein levels of retinoblastoma tumor suppressor (RB1) strongly correlate with the degree of sensitivity to GLUT1 inhibition in TNBC, where RB1-negative cells are insensitive to GLUT1 inhibition. Collectively, our results highlight a strong and targetable RB1-GLUT1 metabolic axis in TNBC and warrant clinical evaluation of GLUT1 inhibition in TNBC patients stratified according to RB1 protein expression levels.

30 January 2017 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
YHYupeng He
Yupeng He
SSSujatha Selvaraju
Sujatha Selvaraju
MCMichael L Curtin
Michael L Curtin
CJClarissa G Jakob
Clarissa G Jakob
HZHaizhong Zhu
Haizhong Zhu
WPWilliam N Pappano
William N Pappano

1 April 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MEMohammad S. Eram
Mohammad S. Eram
SBSusan P. Bustos
Susan P. Bustos
ELEvelyne Lima-Fernandes
Evelyne Lima-Fernandes
ASAlena Siarheyeva
Alena Siarheyeva
GSGuillermo Senisterra
Guillermo Senisterra
MVMasoud Vedadi
Masoud Vedadi
PRDM9 (PR domain-containing protein 9) is a meiosis-specific protein that trimethylates H3K4 and controls the activation of recombination hot spots. It is an essential enzyme in the progression of early meiotic prophase. Disruption of the PRDM9 gene results in sterility in mice. In human, several PRDM9 SNPs have been implicated in sterility as well. Here we report on kinetic studies of H3K4 methylation by PRDM9 in vitro indicating that PRDM9 is a highly active histone methyltransferase catalyzing mono-, di-, and trimethylation of the H3K4 mark. Screening for other potential histone marks, we identified H3K36 as a second histone residue that could also be mono-, di-, and trimethylated by PRDM9 as efficiently as H3K4. Overexpression of PRDM9 in HEK293 cells also resulted in a significant increase in trimethylated H3K36 and H3K4 further confirming our in vitro observations. Our findings indicate that PRDM9 may play critical roles through H3K36 trimethylation in cells.

1 September 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
GDGeneviève Deblois
Geneviève Deblois
STSeyed Ali Madani Tonekaboni
Seyed Ali Madani Tonekaboni
GGGiacomo Grillo
Giacomo Grillo
CMConstanza Martinez
Constanza Martinez
YKYunchi Ingrid Kao
Yunchi Ingrid Kao
MLMathieu Lupien
Mathieu Lupien
Tumor progression upon treatment arises from preexisting resistant cancer cells and/or adaptation of persister cancer cells committing to an expansion phase. Here, we show that evasion from viral mimicry response allows the growth of taxane-resistant triple-negative breast cancer (TNBC). This is enabled by an epigenetic state adapted to taxane-induced metabolic stress, where DNA hypomethylation over loci enriched in transposable elements (TE) is compensated by large chromatin domains of H3K27me3 to warrant TE repression. This epigenetic state creates a vulnerability to epigenetic therapy against EZH2, the H3K27me3 methyltransferase, which alleviates TE repression in taxane-resistant TNBC, leading to double-stranded RNA production and growth inhibition through viral mimicry response. Collectively, our results illustrate how epigenetic states over TEs promote cancer progression under treatment and can inform about vulnerabilities to epigenetic therapy. Significance: Drug-resistant cancer cells represent a major barrier to remission for patients with cancer. Here we show that drug-induced metabolic perturbation and epigenetic states enable evasion from the viral mimicry response induced by chemotherapy in TNBC. These epigenetic states define a vulnerability to epigenetic therapy using EZH2 inhibitors in taxane-resistant TNBC. See related commentary by Janin and Esteller, p. 1258. This article is highlighted in the In This Issue feature, p. 1241

1 April 2011 in EMBO Reports
Verified
Journal Article
Open access
PDF file
EGEva Galan-Moya
Eva Galan-Moya
AGArmelle Le Guelte
Armelle Le Guelte
ELEvelyne Lima‐Fernandes
Evelyne Lima‐Fernandes
CTCécile Thirant
Cécile Thirant
JDJulie Dwyer
Julie Dwyer
JGJulie Gavard
Julie Gavard
Glioma stem‐cells are associated with the brain vasculature. However, the way in which this vascular niche regulates stem‐cell renewal and fate remains unclear. Here, we show that factors emanating from brain endothelial cells positively control the expansion of long‐term glioblastoma stem‐like cells. We find that both pharmacological inhibition of and RNA interference with the mammalian target of rapamycin (mTOR) pathway reduce their spheroid growth. Conversely, the endothelial secretome is sufficient to promote this mTOR‐dependent survival. Thus, interfering with endothelial signals might present opportunities to identify treatments that selectively target malignant stem‐cell niches.